Overexpression of Pim-1 during progression of prostatic adenocarcinoma

Journal of Clinical Pathology

Volumn 59, Issue 3, 2006, Pages 285-288

  Cibull, T L ^b,c   Jones, T D ^b,c   Li, L ^b,c   Eble, J N ^b,c   Baldridge, L Ann ^b,c   Malott, S R ^b,c   Luo, Y ^c   Cheng, L ^a,b,c  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE PIM 1; PRECANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; SEMINAL VESICLE;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-PIM-1; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33644779115     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.027672     Document Type: Article

References (31)

1. Meeker TC, Nagarajan L, ar-Rushdi A, et al. Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. Oncogene Res 1987;1:87-101.
2. Wang Z, Weaver M. PIM-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorgenesis. J Vet Sci 2001:167-79.
3. Telerman A, Amson R, Zakut-Houri R, et al. Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity. Mol Cell Biol 1988;4:1498-503.
4. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991;10:655-64.
5. Liang H, Hittelman W, Nagarajan L. Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1. Arch Biochem Biophys 1996;330:259-65.
6. Hoover DS, Wingett DG, Zhang J, et al. Pim-1 protein expression is regulated by its 5′-untranslated region and translation initiation factor elF-4E. Cell Growth Differ 1997;8:1371-80.
7. Padma R, Nagarajan L. The human PIM-1 gene product is a protein serine kinase. Cancer Res 1991;51:2486-9.
8. Leverson JD, Koskinen PJ, Orrico FC, et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 1998;2:417-25.
9. Schmidt T, Karsunky H, Rodel B, et al. Evidence implicating Gfi-1 and Pim-1 in pre-T-cell differentiation steps associated with beta-selection. EMBO J 1998;17:5349-59.
10. Lilly M, Sandholm J, Cooper JJ, et al. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999;18:4022-31.
11. Mochizuki T, Kitanaka C, Noguchi K, et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999;274:18659-66.
12. Leduc I, Karsunky H, Mathieu N, et al. The Pim-1 kinase stimulates maturation of TCRbeta-deficient T cell progenitors: implications for the mechanism of Pim-1 action. Int Immunol 2000;12:l389-96.
13. Dhanasekaran S, Barrette T, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
14. Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002;32:331.
15. Rainio E, Sandholm J, Koskinen P. Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 2002;168:1524-7.
16. Roh M, Gary B, Song C, et al. Over-expression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 2003;63:8079-84.
17. Pehola K, Paukku K, Aho T, et al. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004;103:3744-50.
18. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
19. Fleming I, Cooper J, Henson D. AJCC cancer staging, 5th ed. Philadelphia: Lippincott-Raven, 1998.
20. Cheng L, Pan C, Zhang JT, et al. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res 2004;10:3064-8.
21. Cheng L, Nagabhushan M, Pretlow TP, et al. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996;148:1375-80.
22. Jiang J, Neubauer BL, Graff JR, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002;160:667-71.
23. Zeng G, Hu Z, Kinch MS, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003;163:2271-6.
24. Mochizuki T, Kitanaka C, Noguchi K, et al. Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation. Oncogene 1997;15:1471-80.
25. Elhvood-Yen K, Graeber T, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
26. Thompson J, Peltola K, Koskinen P, et al. Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1. Lab Invest 2003;83:1301-9.
27. Valdman A, Fang X, Pang ST, et al. Pim-1 expression in prostatic intraepithelial neoplasia and prostate cancer [abstract]. Mod Pathol 2004;17:183A.
28. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-7.
29. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-6.
30. Greene DR, Egawa S, Neerhut G, et al. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol 1991;146:1069-76.
31. Noguchi M, Stamey TA, McNeal JE, et al. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000;163:1751-5.